Sinovac Life Sciences Co., Ltd.

This study is testing a new 24-strain pneumococcal vaccine (PCV24) in healthy children aged 2 months to 23 months. The main goal is to see if the vaccine is safe and if it triggers a good immune response against the bacteria that cause pneumonia and other infections. It will be c…

This study is testing a new version of a vaccine designed to protect infants and young children from serious pneumococcal infections, like certain types of pneumonia and meningitis. It will involve about 3080 healthy children, from 6 weeks old up to age 5, to see if the new vacci…

This study is testing a new vaccine designed to protect children from serious infections like pneumonia and meningitis. It will compare the new vaccine's safety and ability to trigger an immune response against an existing, approved vaccine. The trial will involve 420 healthy chi…